Status:
COMPLETED
COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
ETH Zurich (Switzerland)
Health Department of the Canton of Basel-Stadt
Conditions:
COVID-19 Infection
Eligibility:
All Genders
18+ years
Brief Summary
The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.
Detailed Description
This study is to analyse the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland. The study aims to validate strategies to measure antibody ...
Eligibility Criteria
Inclusion
- tested positive for COVID-19 in Baselland
- tested negative for COVID-19 in Baselland. Specifically, needed to show symptoms to be able to deduce cross reactivities.
Exclusion
- continuous steroid therapy / chemotherapy / immunsuppressiva
- subject is treated for cancer
- severe autoimmune disease
Key Trial Info
Start Date :
April 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
477 Patients enrolled
Trial Details
Trial ID
NCT04483908
Start Date
April 10 2020
End Date
December 31 2021
Last Update
November 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Health, Economics and Health Directorate Canton Basel-Land
Liestal, Switzerland, 4410